Successful Use of a Multidisciplinary Approach to Treat a Perforated Duodenal Malignant Lymphoma in an Elderly Patient

Table 1

Cases of perforated duodenal lymphoma reported in Japan.

Number	Reference	Age/sex	Sites of duodenum	Lymphoma type	Time of perforation	Surgery	Chemotherapy	Radiotherapy	Prognosis	Cause(s) of death
1	[22]	65/M	1st	DLBCL	At presentation	Pancreaticoduodenectomy	CHOP	−	Alive 9+ months	−
2	[23]	61/M	4th	T-cell lymphoma	After two cycles of SMILE	Argon plasma coagulation	Etoposide+ CHOP SMILE	−	Unknown	−
3	[24]	82/M	4th	T-cell lymphoma	After 6 cycles of CHOP	Partial resection	CHOP	−	12 months	Abdominal abscess
4	[25]	70/F	2nd	DLBCL	At presentation	Simple closure, peritoneal patch	R-CHOP	+	Alive 304 days	Sepsis
5	Our case	75/F	3rd	DLBCL	Day 21 after surgery, before chemotherapy	Gastrojejunostomy	R R-mini CHP R-CHP R-CHOP	+	Alive 4+ years	−

DLBCL = diffuse large B cell lymphoma; R-CHOP = rituximab (R), cyclophosphamide (C), doxorubicin (H), vincristine (O), prednisolone (P); CHP = cyclophosphamide (C), doxorubicin (H), prednisolone (P); SMILE = steroid (S), methotrexate (M), ifosfamide (I), L-asparaginase (L), etoposide (E).